Muengtaweepongsa S, Panpattanakul V. Is medical management useful in Moyamoya disease? World J Clin Cases 2024; 12(3): 466-473 [PMID: 38322475 DOI: 10.12998/wjcc.v12.i3.466]
Corresponding Author of This Article
Sombat Muengtaweepongsa, MD, Professor, Center of Excellence in Stroke, Division of Neurology, Department of Medicine, Faculty of Medicine, Thammasat University, Rangsit Campus, No. 99/209 Paholyothin Rd., Klonglaung 12120, Pathum Thani, Thailand. musombat@tu.ac.th
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Sombat Muengtaweepongsa, Center of Excellence in Stroke, Division of Neurology, Department of Medicine, Faculty of Medicine, Thammasat University, Rangsit Campus, Klonglaung 12120, Pathum Thani, Thailand
Vatcharasorn Panpattanakul, Division of Neurology, Department of Internal Medicine, School of Medicine, University of Phayao, Phayao 56000, Thailand
Co-first authors: Sombat Muengtaweepongsa and Vatcharasorn Panpattanakul.
Author contributions: Muengtaweepongsa S and Panpattanakul V contributed equally to this work; Muengtaweepongsa S contributed to conception and design of the work, drafting and critical revision of the article, and gave final approval; Panpattanakul V contributed to conception and design of the work, data collection, drafting and critical revision of the article.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sombat Muengtaweepongsa, MD, Professor, Center of Excellence in Stroke, Division of Neurology, Department of Medicine, Faculty of Medicine, Thammasat University, Rangsit Campus, No. 99/209 Paholyothin Rd., Klonglaung 12120, Pathum Thani, Thailand. musombat@tu.ac.th
Received: October 13, 2023 Peer-review started: October 13, 2023 First decision: November 22, 2023 Revised: November 24, 2023 Accepted: January 5, 2024 Article in press: January 5, 2024 Published online: January 26, 2024 Processing time: 96 Days and 17.4 Hours
Core Tip
Core Tip: Moyamoya disease (MMD) involves progressive arterial stenosis, leading to cerebral infarctions and hemorrhages. Key treatments include revascularization surgery and supplementary medical therapy. Antithrombotic management, crucial for ischemic stroke prevention in MMD, requires a careful balance due to bleeding risks. Understanding cerebral infarction pathways, involving hemodynamic impairment and thromboembolism, is essential. Transcranial doppler is useful for emboli detection and screening. Antiplatelet therapy, especially Acetylsalicylic acid, is common, but its efficacy varies. Antihypertensive management is recommended during initial hemorrhage phases, while lipid-lowering strategies like statins show potential but need more research for specific guidelines in MMD.
